Digitala Vetenskapliga Arkivet

Endre søk
Begrens søket
123 1 - 50 of 110
RefereraExporteraLink til resultatlisten
Permanent link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Treff pr side
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Forfatter A-Ø
  • Forfatter Ø-A
  • Tittel A-Ø
  • Tittel Ø-A
  • Type publikasjon A-Ø
  • Type publikasjon Ø-A
  • Eldste først
  • Nyeste først
  • Skapad (Eldste først)
  • Skapad (Nyeste først)
  • Senast uppdaterad (Eldste først)
  • Senast uppdaterad (Nyeste først)
  • Disputationsdatum (tidligste først)
  • Disputationsdatum (siste først)
  • Standard (Relevans)
  • Forfatter A-Ø
  • Forfatter Ø-A
  • Tittel A-Ø
  • Tittel Ø-A
  • Type publikasjon A-Ø
  • Type publikasjon Ø-A
  • Eldste først
  • Nyeste først
  • Skapad (Eldste først)
  • Skapad (Nyeste først)
  • Senast uppdaterad (Eldste først)
  • Senast uppdaterad (Nyeste først)
  • Disputationsdatum (tidligste først)
  • Disputationsdatum (siste først)
Merk
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 1. Adams, D.
    et al.
    Coelho, T.
    Conceicao, E.
    Waddington-Cruz, M.
    Schmidt, H.
    Buades, J.
    Campistol, J. M.
    Pouget, J.
    Berk, J. L.
    Polydefkis, M.
    Ziyadeh, N.
    Partisano, A. M.
    Chen, J.
    Gollob, J.
    Suhr, Ole B.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    PHASE 2 OPEN-LABEL EXTENSION (OLE) STUDY OF PATISIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 5, s. A211-A212Artikkel i tidsskrift (Annet vitenskapelig)
  • 2. Banefelt, J.
    et al.
    Hallberg, S.
    Fox, K. M.
    Mesterton, J.
    Paoli, C. J.
    Johansson, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Levin, L. A.
    Sobocki, P.
    Gandra, S. R.
    Work Productivity Loss And Indirect Costs Associated With New Cardiovascular Events In High-Risk Patients With Hyperlipidemia - Estimates From Population-Based Register Data In Sweden2014Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, nr 7, s. A327-A328, artikkel-id CV2Artikkel i tidsskrift (Annet vitenskapelig)
  • 3. Banefelt, J.
    et al.
    Hallberg, S.
    Gandra, S. R.
    Mesterton, J.
    Fox, K. M.
    Paoli, C. J.
    Johansson, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Levin, L. A.
    Sobocki, P.
    Burden Of Hyperlipidemia Resulting From Productivity Loss - Estimates From Population-Based Register Data In Sweden2014Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, nr 7, s. A491-A492, artikkel-id PCV110Artikkel i tidsskrift (Annet vitenskapelig)
  • 4.
    Berg, Jenny
    et al.
    Karolinska Institute, Sweden; OptumInsight, Sweden.
    Lindgren, Peter
    Karolinska Institute, Sweden; IVBAR, Sweden.
    Mejhert, Marit
    Ersta Hospital, Sweden; Karolinska Institute, Sweden.
    Edner, Magnus
    Karolinska University Hospital, Sweden.
    Dahlström, Ulf
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för kardiovaskulär medicin. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Hjärt- och Medicincentrum, Kardiologiska kliniken US.
    Kahan, Thomas
    Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
    Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry2015Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 4, s. 439-448Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: There is limited information on drivers of utilities in patients with chronic heart failure (CHF). Objectives: To analyze determinants of utility in CHF and drivers of change over 1 year in a large sample from clinical practice. Methods: We included 5334 patients from the Swedish Heart Failure Registry with EuroQol five-dimensional questionnaire information available following inpatient or outpatient care during 2008 to 2010; 3495 had 1-year follow-up data Utilities based on Swedish and UK value sets were derived. We applied ordinary least squares (OLS) and two-part models for utility at inclusion and OLS regression for change over 1 year, all with robust standard errors. We assessed the predictive accuracy of both models using cross-validation. Results: Patients mean age was 73 years, 65% were men, 19% had a left ventricular ejection fraction of 50% or more, 23% had 40% to 49%, 27% had 30% to 39%, and 31% had less than 30%. For both models and value sets, utility at inclusion was affected by sex, age, New York Heart Association class, ejection fraction, hemoglobin, blood pressure, lung disease, diabetes, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, nitrates, antiplatelets, and diuretics. The OLS model performed slightly better than did the two-part model on a population level and for capturing utility ranges. Change in utility over 1 year was influenced by age, sex, and (measured at inclusion) disease duration, New York Heart Association class, blood pressure, ischemic heart disease, lung disease, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and antiplatelets. Conclusions: Utilities in CHF and their change over time are influenced by diverse demographic and clinical factors. Our findings can be used to target clinical interventions and for economic evaluations of new therapies.

  • 5.
    Bergthorsdottir, R
    et al.
    Sahlgrenska University Hospital, Gothenburg, Sweden.
    Nilsson, A G
    Sahlgrenska University Hospital, Gothenburg, Sweden.
    Gillberg, P
    Shire, Danderyd, Sweden.
    Ekman, Bertil
    Östergötlands Läns Landsting, Hjärt- och Medicincentrum, Endokrinmedicinska kliniken. Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för kardiovaskulär medicin. Linköpings universitet, Medicinska fakulteten.
    Wahlberg, Jeanette
    Östergötlands Läns Landsting, Hjärt- och Medicincentrum, Endokrinmedicinska kliniken. Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för kardiovaskulär medicin. Linköpings universitet, Medicinska fakulteten.
    Health-Related Quality of Life In Patients With Adrenal Insufficiency Receiving Plenadren Compared With Immediate-Release Hydrocortisone.2015Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 7, s. A616-Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background

    Previous studies in patients with primary adrenal insufficiency (PAI) on conventional replacement therapy suggest decreased health-related quality of life (HRQoL), and that patients report more frequently fatigue, increased anxiety and inability to work compared to background population.

    Objectives

    To study self-reported health status with EQ-5D in patients with PAI. Patients treated with Plenadren (modified-release hydrocortisone) were compared with patients treated with immediate release hydrocortisone (IRHC) replacement therapy.

    Methods

    This was a cross-sectional, multi-centre, non-interventional survey of patients with PAI receiving Plenadren or immediate release hydrocortisone (IRHC) replacement.

    Subjects

    One hundred thirty-four adult patients with PAI of whom 36 (19 females [53%]) were treated with Plenadren and 98 (77 females [79%]) were treated with IRHC, were included.

    MAIN OUTCOME MEASURE

    HRQoL described by the EQ-5D, a generic preference-based measure of health.

    RESULTS

    Patients on Plenadren and on IRHC had a mean ± SD age of 53.1 ± 12.7 years and 48.0 ± 13.1 years, respectively (P=0.043). The majority of the patients were diagnosed more than 5 years ago (69%). The mean ± SD daily Plenadren and IRHC doses were 27.0 ± 6.8 mg and 26.6 ± 10.9 mg, respectively (P=0.807). 47% of the Plenadren patients had been receiving Plenadren and 82% of the IRHC patients had been receiving IRHC for more than 3 years. Patients receiving Plenadren had better HRQoL measured by the EQ-5D questionnaire compared to patients replaced with IRHC (0.76 ± 0.18 vs 0.68 ± 0.18, respectively [P=0.040]).

    CONCLUSIONS

    Replacement therapy with Plenadren in patients with PAI confers measurable benefit on HRQoL relative to IRHC as estimated by the EQ-5D questionnaire, and may therefore be advantageous when compared to IRHC substitution.

  • 6.
    Bjorstad, A.
    et al.
    Nord Hlth Econ, Gothenburg, Sweden..
    Marlow, T.
    Nord Hlth Econ, Gothenburg, Sweden..
    Lesen, E.
    Nord Hlth Econ, Gothenburg, Sweden..
    Bollano, E.
    Sahlgrens Univ Hosp, Gothenburg, Sweden..
    Marteau, F.
    Ipsen Pharma, Boulogne, France..
    Gabriel, S.
    Ipsen Pharma, Boulogne, France..
    Welin, Staffan
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Onkologisk endokrinologi.
    Fcuilly, M.
    Ipsen Pharma, Boulogne, France..
    Real-World Resource Use And Costs Of Carcinoid Heart Disease In Patients With Neuroendocrine Tumors: A Retrospective Swedish Study2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A552-A552Artikkel i tidsskrift (Annet vitenskapelig)
  • 7. Boman, K.
    et al.
    Lindmark, Krister
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin.
    Stålhammar, J.
    Olofsson, M.
    Costa-Scharplatz, M.
    Fonseca, A. F.
    Wirta, Bruce S.
    Castelo-branco, A.
    Törnblom, M.
    Wikström, G.
    Total annual healthcare costs of heart failure between 2005 and 2014: a retrospective, population-based study in Sweden2018Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 21, s. S100-S100Artikkel i tidsskrift (Annet vitenskapelig)
  • 8. Borg, S.
    et al.
    Gerdtham, U. G.
    Rydén, Tobias
    KTH, Skolan för teknikvetenskap (SCI), Matematik (Inst.), Matematisk statistik.
    Munkholm, P.
    Odes, S.
    Langholz, E.
    Moum, B.
    Annese, V
    Bagnoli, S.
    Beltrami, M.
    Clofent, J.
    Friger, M.
    Milla, M.
    Mouzas, I
    O'Morain, C.
    Politi, P.
    Riis, L.
    Stockbrugger, R.
    Tsianos, E.
    Vardi, H.
    Lindgren, S.
    Estimation Of A Markov Chain For Crohn's Disease And Classification Of Patients Into Disease Phenotypes, In Eight Countries Using Individual Longitudinal Data Aggregated Over Time2012Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, nr 7, s. A466-A467Artikkel i tidsskrift (Annet vitenskapelig)
  • 9. Bostrom, P.
    et al.
    Lovkvist, L.
    Gustafsson, M.
    Alexandersson, O.
    Bruse, C.
    Liffner, C.
    Holmberg, J.
    Edlund, M.
    Olovsson, Matts
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Obstetrik & gynekologi.
    Cost of illness in women with endometriosis2012Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, nr 7, s. A538-A538Artikkel i tidsskrift (Annet vitenskapelig)
  • 10. Brobert, G.
    et al.
    Garcia Rodriguez, L. A.
    Garbe, E.
    Bezemer, I. D.
    Layton, D.
    Friberg, L.
    Suzart-Woischnik, K.
    Alderson, J.
    Winchester, C.
    Herings, R. M. C.
    Jobski, K.
    Schink, T.
    Shakir, S.
    Soriano-Gabarro, M.
    Wallander, Mari-Ann
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Development of a Collaborative European Pharmacoepidemiologic Post-Authorization Safety Study (PASS) Programme Examining Rivaroxaban Use in Routine Clinical Practice2014Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, nr 7, s. A473-A474, artikkel-id PCV6Artikkel i tidsskrift (Annet vitenskapelig)
  • 11. Caccamisi, Andrea
    et al.
    Jörgensen, Leif
    Dalianis, Hercules
    Stockholms universitet, Samhällsvetenskapliga fakulteten, Institutionen för data- och systemvetenskap.
    Rosenlund, Mats
    PRM92 - Automatic Extraction and Classification of Patients’ Smoking Status from Free Text Using Natural Language Processing2016Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 19, nr 7, artikkel-id A373Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objectives

    To develop a machine learning algorithm for automatic classification of smoking status (smoker, ex-smoker, non-smoker and unknown status) in EMRs, and validate the predictive accuracy compared to a rule-based method. Smoking is a leading cause of death worldwide and may introduce confounding in research based on real world data (RWD). Information on smoking is often documented in free text fields in Electronic Medical Records (EMRs), but structured RWD on smoking is sparse.

    Methods

    32 predictive models were trained with the Weka machine learning suite, tweaking sentence frequency, classifier type, tokenization and attribute selection using a database of 85,000 classified sentences. The models were evaluated using F-Score and Accuracy based on out-of-sample test data including 8,500 sentences. The error weight matrix was used to select the best model, assigning a weight to each type of misclassification and applying it to the models confusion matrices.

    Results

    The best performing model was based on the Support Vector Machine (SVM) Sequential Minimal Optimization (SMO) classifier using a polynomial kernel with parameter C equal to 6 and a combination of unigrams and bigrams as tokens. Sentence frequency and attributes selection did not improve model performance. SMO achieved 98.25% accuracy and 0.982 F-Score versus 79.32% and 0.756, respectively, for the rule-based model.

    Conclusions

    A model using machine learning algorithms to automatically classify patients smoking status was successfully developed. This algorithm would enable automatic assessment of smoking status directly from EMRs, obviating the need to extract complete case notes and manual classification.

  • 12. Chadda, S.
    et al.
    Larkin, M.
    Jones, C.
    Sykes, D.
    Barber, B.
    Zhao, Z.
    Gao, S.
    Bengtsson, Nils-Olof
    Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi.
    The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: a european perspective2011Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 14, nr 3, s. A173-A173Artikkel i tidsskrift (Fagfellevurdert)
  • 13. Chen, Gang
    et al.
    Flynn, Terry
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Centrum för forsknings- och bioetik.
    Stevens, Katherine
    Brazier, John
    Huynh, Elisabeth
    Sawyer, Michael
    Roberts, Rachel
    Ratcliffe, Julie
    Assessing the Health-Related Quality of Life of Australian Adolescents: An Empirical Comparison of the Child Health Utility 9D and EQ-5D-Y Instruments2015Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 4, s. 432-438Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objectives: To examine the performance of two recently developed preference-based instruments-the Child Health Utility 9D (CHU9D) and the EuroQol five-dimensional questionnaire Youth version (EQ-5D-Y)-in assessing the health related quality of life (HRQOL) of Australian adolescents. Methods: An online survey including the CHU9D and the EQ-5D-Y, self-reported health status, and a series of sociodemographic questions was developed for administration to a community-based sample of adolescents (aged 11-17 years). Individual responses to both instruments were translated into utilities using scoring algorithms derived from the Australian adult general population. Results: A total of 2020 adolescents completed the online survey. The mean +/- SD utilities of the CHU9D and the EQ-5D-Y were very similar (0.82 +/- 0.13 and 0.83 +/- 0.19, respectively), and the intraclass correlation coefficient (0.80) suggested good levels of agreement. Both instruments were able to discriminate according to varying levels of self-reported health status (P < 0.001). Although exhibiting good levels of agreement overall, some wide divergences were apparent at an individual level. Conclusions: The study results are encouraging and illustrate the potential for both the CHU9D and the EQ-5D-Y to be more widely used for measuring and valuing the HRQOL of adolescent populations in Australia and internationally. Generating adolescent-specific scoring algorithms pertaining to each instrument and an empirical comparison of the resulting utilities is a natural next step. More evidence is required from the application of the CHU9D and the EQ-5D-Y in specific patient groups in adolescent health settings to inform the choice of instrument for measuring and valuing the HRQOL for the economic evaluation of adolescent health care treatments and services.

  • 14. Costa-Scharplatz, M.
    et al.
    Tambour, M.
    Henriksson, F.
    Ställberg, Björn
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Cost-Effectiveness Of Glycopyrronium Compared To Tiotropium In Copd Patients From A Swedish Societal Perspective2013Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 16, nr 7, s. A371-A372Artikkel i tidsskrift (Annet vitenskapelig)
  • 15.
    Delgado-Ortega, L.
    et al.
    AstraZeneca Spain, Madrid.
    Lopez-Sendon, J. L
    Hospital Universitario de la Paz, Madrid, Spain.
    Heras Fortuny, M.
    Hospital Clinic, Barcelona, Spain.
    Alvarez Sanz, C.
    AstraZeneca Spain, Madrid.
    Nikolic, Elisabet
    Linköpings universitet, Institutionen för medicin och hälsa, Utvärdering och hälsoekonomi. Linköpings universitet, Hälsouniversitetet.
    Mellström, C.
    Astrazeneca R&D, Lomma, Sweden.
    Wallentin, L
    Uppsala University, Sweden.
    PCV45 Health Economic Evaluation of Ticagrelor in Patients with Acute Coronary Patients (ACS) Based on the Plato Study from A Spanish Health Care Perspective2011Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 14, nr 7, s. A372-A372Artikkel i tidsskrift (Annet vitenskapelig)
    Abstract [en]

    Objectives

    PLATO was a multi centered, double blind, randomized study that included 18,624 ACS patients from 43 countries, comparing ticagrelor + aspirin versus clopidogrel + aspirin. The PLATO demonstrated that ticagrelor was superior on the primary composite endpoint: myocardial infarction, stroke, cardiovascular death (HR 0.84, 95% CI: 0.77 to 0.92) without an increase in major bleedings compared to clopidogrel, and whether the strategy of choice was invasive or conservative. The aim of this analysis is to estimate direct health care costs from a Spanish health care perspective (excluding drug costs because ticagrelor price has not yet been established).

    Methods

    Resource utilization was pre specified in the PLATO trial and included hospitalization bed days, investigations, interventions and blood products. Direct health care costs per patient at 12 months were estimated by multiplying the resource use with Spanish unit costs derived from the Spanish database e-salud, the GRDs of the Ministry of Health, published literature, and the CMBD 2008.

    Results

    Ticagrelor resulted in numerically fewer bed days (mean difference per patient 0.21, 95% CI -0.16 to 0.59), PCIs (mean difference per patient 0.01, 95% CI -0.01 to 0.03) and CABGs (mean difference per patient 0.01, 95% CI: 0.00 to 0.01). Ticagrelor is associated with €341 reduction per patient (95% CI: 31 to 652) in healthcare costs at 12 months compared to clopidogrel. The reduction in healthcare costs was mainly due to fewer hospital days and cardiovascular interventions in the ticagrelor group. The reduction in cost increased over the 12-month treatment period consistent with the rate of clinical events over time in the PLATO study.

    Conclusions

    Treatment with ticagrelor is associated with cost savings in patients with ACS at 12 months compared with clopidogrel (excluding drug costs) from a Spanish health care perspective. However, the total cost savings will depend on drug price, data not available yet.

  • 16.
    Doward, Lynda C.
    et al.
    Galen Research, Manchester.
    Meads, David M.
    Galen Research, Manchester.
    Fisk, John
    Dalhousie University, Halifax, Nova Scotia.
    Twiss, James
    Galen Research, Manchester.
    Hagell, Peter
    Lund University.
    Oprandi, Nadia C.
    University of Verona.
    Grand'Maison, François
    Université de Sherbrooke, Sherbrooke, Quebec.
    Bhan, Virender
    Dalhousie University, Halifax, Nova Scotia.
    Arbizu, Txomin
    University of Barcelona.
    Kohlmann, Thomas
    Greifswald University.
    Brassat, David
    Department of Neurology and INSERM U536, University of Toulouse.
    Eckert, Benjamin J.
    Novartis Pharmaceuticals, East Hanover, New Jersey.
    McKenna, Stephen P.
    Galen Research, Manchester.
    International development of the Unidimensional Fatigue Impact Scale (U-FIS)2010Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 13, nr 4, s. 463-468Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    OBJECTIVE: The 22-item Unidimensional Fatigue Impact Scale (U-FIS) provides an index of the impact of fatigue on patients with multiple sclerosis (MS). The objective is to produce eight new language versions of the U-FIS: Canadian-English, Canadian-French, French, German, Italian, Spanish, Swedish, and US-English.

    METHODS: The U-FIS was translated via two translation panels. Cognitive debriefing interviews conducted with patients in each country assessed face and content validity. Scaling and psychometric properties were assessed via survey data with patients in each country completing the U-FIS, Nottingham Health Profile (NHP), and demographic questions.

    RESULTS: Cognitive debriefing interviews demonstrated U-FIS acceptability. Analysis of postal survey data showed all new language versions to be unidimensional. Reliability was high, with test-retest correlations and internal-consistency coefficients exceeding 0.85. Initial evidence of validity was provided by moderate to high correlations with NHP scales. The U-FIS was able to discriminate between groups based on employment status, perceived MS severity, and general health.

    CONCLUSION: The U-FIS is a practical new measure of the impact of fatigue. It was successfully adapted into eight new languages to broaden availability for researchers. Psychometric analyses indicated that the new language versions were unidimensional and reproducible with promising construct validity.

  • 17.
    Evans, M.
    et al.
    University Hospital Llandough, Cardiff, UK.
    Ridderstråle, M.
    Steno Diabetes Center, Gentofte, Denmark.
    Jensen, H. H.
    Incentive, Holte, Denmark.
    Bøgelund, M.
    Novo Nordisk Ltd., Gatwick, United Arab Emirates.
    Jensen, M. M.
    Novo Nordisk, Copenhagen, Denmark.
    Ericsson, Å.
    Novo Nordisk Scandinavia AB, Malmö, Sweden.
    Jendle, Johan
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Quantifying The Short-Term Impact of Changes In Hba1c, Weight And Insulin Regimen on Health Related Quality-of-Life2015Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 7, s. A616-A616Artikkel i tidsskrift (Fagfellevurdert)
  • 18.
    Feldman, Inna
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Socialmedicin/CHAP.
    Virtanen, S.
    Karolinska Inst, Stockholm, Sweden.
    Galanti, M. R.
    Karolinska Inst, Stockholm, Sweden.
    Johansson, P.
    Publ Hlth & Econ, Huddinge, Sweden.
    Economic Evaluation Of A Brief Counselling For Smoking Cessation In Dentistry: A Case Study Comparing Two Health Economic Models2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A751-A751Artikkel i tidsskrift (Annet vitenskapelig)
  • 19.
    Forbes, C. A.
    et al.
    Kleijnen Systemat Reviews Ltd, York, N Yorkshire, England..
    Deshpande, S.
    Kleijnen Systemat Reviews Ltd, York, N Yorkshire, England..
    Sorio-Vilela, F.
    Amgen Europe, Zug, Switzerland.;EEMEA, Zug, Switzerland..
    Kutikova, L.
    Amgen Europe GmbH, Zug, Switzerland..
    Duffy, S.
    Kleijnen Systemat Reviews Ltd, York, N Yorkshire, England..
    Gouni-Berthold, I
    Univ Cologne, Cologne, Germany..
    Hagström, Emil
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Kardiologi.
    Comparison Of Methods To Measure Patient Adherence And Persistence With Pharmacological Therapy: A Systematic Review2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A620-A620Artikkel i tidsskrift (Annet vitenskapelig)
  • 20. Fränneby, Ulf
    et al.
    Sandblom, Gabriel
    Nyrén, Olof
    Nordin, Pär
    Gunnarsson, Ulf
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper.
    Self-reported adverse events after groin hernia repair, a study based on a national register2008Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 11, nr 5, s. 927-932Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objectives: In most clinics, follow-up after inguinal hernia surgery is not a routine procedure and complications may pass unnoticed, thus impairing quality assessment. The aim of this study was to investigate the frequency, spectrum, and risk factors of short-term adverse events after groin hernia repair. Methods: All patients aged 15 years or older with a primary unilateral inguinal or femoral hernia repair recorded in the Swedish Hernia Register (SHR) between November 1 and December 31, 2002 were sent a questionnaire asking about complications within the first 30 postoperative days. Results: Of the 1643 recorded patients, 1448 (88.1%) responded: 1341 (92.6%) were men and 107 (7.4%) women, mean age 59 years. There were 195 (11.9%) nonresponders. Postoperative complications reported in the questionnaire were hematoma in 203 (14.0%) patients, severe pain in 168 (11.6%), testicular pain in 120 (8.3%), and infection in 105 (7.3%). Adverse events were reported in the questionnaire by 391 (23.8%) patients, whereas only 85 (5.2%) were affected according to the SHR. Risk factors for postoperative complications were age below the median (59 years) among the studied hernia patients (OR 1.36; 95% CI 1.06-1.74) and laparoscopic repair (OR 2.66; 95% CI 1.17-6.05). Conclusion: Questionnaires provide valuable additional information concerning postoperative complications. We recommend that they become an integrated part of routine postoperative assessment.

  • 21.
    Fränneby, Ulf
    et al.
    Department of Surgery, Södersjukhuset, Stockholm, Sweden.
    Sandblom, Gabriel
    Lund University Hospital, Lund, Sweden.
    Nyrén, Olof
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
    Nordin, Pär
    Umeå universitet, Medicinska fakulteten, Institutionen för kirurgisk och perioperativ vetenskap, Kirurgi.
    Gunnarsson, Ulf
    Akademiska Sjukhuset, Uppsala, Sweden.
    Self-reported adverse events after groin hernia repair, a study based on a national register.2008Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 11, nr 5, s. 927-932Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    OBJECTIVES: In most clinics, follow-up after inguinal hernia surgery is not a routine procedure and complications may pass unnoticed, thus impairing quality assessment. The aim of this study was to investigate the frequency, spectrum, and risk factors of short-term adverse events after groin hernia repair. METHODS: All patients aged 15 years or older with a primary unilateral inguinal or femoral hernia repair recorded in the Swedish Hernia Register (SHR) between November 1 and December 31, 2002 were sent a questionnaire asking about complications within the first 30 postoperative days. RESULTS: Of the 1643 recorded patients, 1448 (88.1%) responded: 1341 (92.6%) were men and 107 (7.4%) women, mean age 59 years. There were 195 (11.9%) nonresponders. Postoperative complications reported in the questionnaire were hematoma in 203 (14.0%) patients, severe pain in 168 (11.6%), testicular pain in 120 (8.3%), and infection in 105 (7.3%). Adverse events were reported in the questionnaire by 391 (23.8%) patients, whereas only 85 (5.2%) were affected according to the SHR. Risk factors for postoperative complications were age below the median (59 years) among the studied hernia patients (OR 1.36; 95% CI 1.06-1.74) and laparoscopic repair (OR 2.66; 95% CI 1.17-6.05). CONCLUSION: Questionnaires provide valuable additional information concerning postoperative complications. We recommend that they become an integrated part of routine postoperative assessment.

  • 22.
    Fust, K.
    et al.
    Optum, Boston, MA USA..
    Maschio, M.
    Optum, Burlington, ON, Canada..
    Pastor, M.
    Optum, Burlington, ON, Canada..
    Kohli, M.
    Optum, Burlington, ON, Canada..
    Weinstein, M. C.
    Harvard TH Chan Sch Publ Hlth, Boston, MA USA..
    Singh, S.
    Sunnybrook Res Inst, Toronto, ON, Canada..
    Pritchard, M.
    Univ Liverpool, Liverpool, Merseyside, England..
    Welin, Staffan
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Onkologisk endokrinologi.
    Marteau, R.
    Ipsen Pharma, Boulogne, France..
    Gabriel, S.
    Ipsen Pharma, Boulogne, France..
    Feuilly, M.
    Ipsen Pharma, Boulogne, France..
    A Budget Impact Model Of The Addition Of Telotristat Ethyl Treatment In Patients With Uncontrolled Carcinoid Syndrome2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A548-A549Artikkel i tidsskrift (Annet vitenskapelig)
  • 23.
    Geale, Kirk
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    Henriksson, M.
    Schmitt-Egenolf, Marcus
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Dermatologi och venereologi.
    The Relationship Between Disease Severity and Quality of Life In Patients With Moderate to Severe Psoriasis2015Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 7, s. A675-A675Artikkel i tidsskrift (Fagfellevurdert)
  • 24.
    Ghatnekar, Ola
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    Glader, Eva-Lotta
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 20012008Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 11, nr 5, s. 862-868Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objective: Atrial fibrillation (AF) is an important risk factor for stroke. It is prevalent in approximately one-fourth of stroke patients, and predictive of worse outcomes. This study aimed to analyze the effect of AF on stroke-related inpatient costs among first-ever stroke patients in Sweden.

    Methods: Hospitalizations and death records were monitored for 3 years in 6611 first-ever stroke patients. For stroke as primary diagnosis, inpatient costs were calculated on the basis of length of stay at different wards. For stroke as secondary diagnosis, costs were based on diagnosis-related groups.

    Results: Patients with AF (24% of all patients) were older (80 years vs. 73 years), had a higher prevalence of hypertension (49% vs. 41%) and/or diabetes (22% vs. 19%), higher risk of experiencing a restroke, and higher case fatality rate (43% vs. 25%) than patients without AF. The average cost per patient over 3 years was euro9004, with no statistically significant difference between AF and non-AF patients. However, a multiple regression analysis showed that the presence of AF resulted in higher costs after considering a number of background factors. Among patients surviving the index event, AF patients had on average euro818 higher inpatient costs over 3 years than non-AF patients (euro10,192 vs. euro9374, P < 0.01). The difference in costs was highest for patients aged <65 years, with a difference of euro4412 (P < 0.01).

    Conclusion: AF-related strokes are associated with higher 3-year inpatient costs than non-AF strokes when controlling for factors such as case fatality rates, other risk factors for stroke, and age.

  • 25. Granstrom, O.
    et al.
    Kjeldsen, S. E.
    Russell, D.
    Thuresson, M.
    Stålhammar, Jan
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Bodegard, J.
    Hedegaard, M.
    Hospitalizations and primary care resource use: A real-life perspective2012Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, nr 4, s. A130-A130Artikkel i tidsskrift (Annet vitenskapelig)
  • 26.
    Gyllensten, Hanna
    et al.
    Nordic School Public Health NHV, Sweden; University of Gothenburg, Sweden; Karolinska Institute, Sweden.
    Jönsson, Anna K
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för läkemedelsforskning. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Diagnostikcentrum, Klinisk farmakologi.
    Hakkarainen, Katja M.
    Nordic School Public Health NHV, Sweden; EPID Research, Finland.
    Svensson, Staffan
    Narhalsan Hjallbo Medical Centre, Finland.
    Hägg, Staffan
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för läkemedelsforskning. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Diagnostikcentrum, Klinisk farmakologi. Jonköping County Council, Sweden.
    Rehnberg, Clas
    Karolinska Institute, Sweden.
    Comparing Methods for Estimating Direct Costs of Adverse Drug Events2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 10, s. 1299-1310Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objectives: To estimate how direct health care costs resulting from adverse drug events (ADEs) and cost distribution are affected by methodological decisions regarding identification of ADEs, assigning relevant resource use to ADEs, and estimating costs for the assigned resources. Methods: ADEs were identified from medical records and diagnostic codes for a random sample of 4970 Swedish adults during a 3-month study period in 2008 and were assessed for causality. Results were compared for five cost evaluation methods, including different methods for identifying ADEs, assigning resource use to ADEs, and for estimating costs for the assigned resources (resource use method, proportion of registered cost method, unit cost method, diagnostic code method, and main diagnosis method). Different levels of causality for ADEs and ADEs contribution to health care resource use were considered. Results: Using the five methods, the maximum estimated overall direct health care costs resulting from ADEs ranged from Sk10,000 (Sk = Swedish krona; similar to(sic)1,500 in 2016 values) using the diagnostic code method to more than Sk3,000,000 (similar to(sic)414,000) using the unit cost method in our study population. The most conservative definitions for ADEs contribution to health care resource use and the causality of ADEs resulted in average costs per patient ranging from Sk0 using the diagnostic code method to Sk4066 (similar to(sic)500) using the unit cost method. Conclusions: The estimated costs resulting from ADEs varied considerably depending on the methodological choices. The results indicate that costs for ADEs need to be identified through medical record review and by using detailed unit cost data. Copyright (C) 2017, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

  • 27.
    Hagell, Peter
    et al.
    Department of Health Sciences, Lund University.
    Hedin, Per-Johan
    Department of Rheumatology, Central Hospital, Falun.
    Meads, David M.
    Galen Research Ltd., Manchester.
    Nyberg, Lennart
    Centre for Languages and Literature, Lund University.
    McKenna, Stephen P.
    Galen Research Ltd., Manchester.
    Effects of method of translation of patient-reported health outcome questionnaires: a randomized study of the translation of the Rheumatoid Arthritis Quality of Life (RAQoL) Instrument for Sweden2010Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 13, nr 4, s. 424-430Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    AIMS: To compare two versions of a questionnaire translated using forward-backward (FB) translation and dual-panel (DP) methodologies regarding preference of wording and psychometric properties.

    METHODS: The Rheumatoid Arthritis Quality of Life instrument was adapted into Swedish by two independent groups using FB and DP methodologies, respectively. Seven out of thirty resulting items were identical. Nonidentical items were evaluated regarding preference of wording by 23 bilingual Swedes, 50 people with rheumatoid arthritis (RA), and 2 lay panels (n = 11). Psychometric performance was assessed from a postal survey of 200 people with RA randomly assigned to complete one version first and the other 2 weeks later.

    RESULTS: Preference did not differ among the 23 bilinguals (P = 0.196), whereas patients and lay people preferred DP over FB item versions (P < 0.0001). Postal survey response rates were 74% (FB) and 75% (DP). There were more missing item responses in the FB than the DP version (6.9% vs. 5.6%; P < 0.0001). Floor/ceiling effects were small (FB, 6.1/0%; DP, 4.4/0.7%) and reliability was 0.92 for both versions. Construct validity was similar for both versions. Differential item functioning by version was detected for five items but cancelled out and did not affect estimated person measures.

    CONCLUSIONS: The DP approach showed advantages over FB translation in terms of preference by the target population and by lay people, whereas there were no obvious psychometric differences. This suggests advantages of DP over FB translation from the patients' perspective, and does not support the commonly held view that FB translation is the "gold standard."

  • 28.
    Hagell, Peter
    et al.
    Department of Health Sciences, Lund University.
    Reimer, Jan
    Department of Neurology, University Hospital, Lund.
    Nyberg, Per
    Department of Health Sciences, Lund University.
    Whose quality of life?: ethical implications in patient-reported health outcome measurement2009Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 12, nr 4, s. 613-617Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    OBJECTIVES: Patient-reported health status questionnaires intend to assess illness and therapy from the patients' perspective. To provide fair and valid assessments, they should be equally relevant to major subsets of respondents. Furthermore, disease-specific measures are assumed to be perceived as more relevant than generic ones. This study assessed these assumptions among people with Parkinson's disease.

    METHODS: Cross-sectional data from 202 people with Parkinson's disease (54% men; mean age, 70) were analyzed regarding patient-rated relevance and predictors of patient-rated poor relevance of two generic [the 36-item Short Form Health Survey (SF-36) and Nottingham Health Profile (NHP)] and one disease-specific [Parkinson's Disease Questionnaire (PDQ-39)] health status questionnaire.

    RESULTS: There were no differences in relevance ratings across the questionnaires. Poorer overall quality of life [odds ratio (OR), 2.459] and mental health (OR, 1.023) were associated with poorer patient-rated relevance of the SF-36, and higher age was associated with poorer patient-rated relevance of the PDQ-39 (OR, 1.040). No significant predictors were found for the NHP.

    CONCLUSIONS: The PDQ-39 failed to meet the assumption that disease-specific scales are more relevant than generic ones. Nevertheless, the most important implication of this study is an ethical one. Because the relevance of the SF-36 and PDQ-39 is perceived as poorer by those who fare least well and by older people, these scales may not reflect the perspectives of these groups. This challenges bioethical principles and threatens scientific validity. Perceived relevance of patient-centered outcomes needs to be considered, or the voice of vulnerable groups may be silenced, fair inferences prohibited, and opportunities for improved care lost.

  • 29. Hallberg, S.
    et al.
    Banefelt, J.
    Fox, K. M.
    Mesterton, J.
    Johansson, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Levin, L. A.
    Sobocki, P.
    Gandra, S. R.
    Treatment Patterns In Hyperlipidemia Patients With New Cardiovascular Events - Estimates From Population-Based Register Data In Sweden2014Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, nr 7, s. A501-A501, artikkel-id PCV162Artikkel i tidsskrift (Annet vitenskapelig)
  • 30. Hallberg, S.
    et al.
    Banefelt, J.
    Mesterton, J.
    Gandra, S. R.
    Fox, K. M.
    Johansson, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Levin, L. A.
    Sobocki, P.
    Health Care Costs Associated With Cardiovascular Events In Patients With Hyperlipidemia - Estimates From Population-Based Register Data In Sweden2014Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, nr 7, s. A492-A492, artikkel-id PCV111Artikkel i tidsskrift (Annet vitenskapelig)
  • 31.
    Hansson-Hedblom, A.
    et al.
    Quantify Res, Stockholm, Sweden..
    Jonsson, E.
    Quantify Res, Stockholm, Sweden..
    Kirketeig, Terje
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper, Anestesiologi och intensivvård.
    Hägg, O.
    Spine Ctr Goteborg, Gothenburg, Sweden..
    Fritzell, P.
    Capio St Goran Hosp, Stockholm, Sweden..
    Borgström, F.
    Capio St Goran Hosp, Stockholm, Sweden..
    Cost Patterns In Patients Treated With Spinal Cord Stimulation Following Spine Surgery-A Register Based Study2016Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 19, nr 7, s. A692-A692Artikkel i tidsskrift (Fagfellevurdert)
  • 32. Hedegaard, M.
    et al.
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Lisspers, Karin
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Ställberg, Björn
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Johansson, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Jorgensen, L.
    Larsson, K.
    Cost Effectiveness Of Budesonide/Formoterol Versus Fluticasone/Salmeterol From A Swedish Health Care Perspective Based On Real-World Effectiveness And Safety In Patients With Copd2013Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 16, nr 3, s. A235-A235Artikkel i tidsskrift (Annet vitenskapelig)
  • 33. Hedegaard, M.
    et al.
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Lisspers, Karin
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Ställberg, Björn
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Johansson, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Jorgensen, L.
    Larsson, K.
    Cost-effectiveness of budesonide/formoterol versus fluticasone/salmeterol based on real-world effectiveness in patients with copd2012Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, nr 7, s. A563-A563Artikkel i tidsskrift (Annet vitenskapelig)
  • 34.
    Heintz, Emelie
    et al.
    Linköpings universitet, Institutionen för medicin och hälsa, Utvärdering och hälsoekonomi. Linköpings universitet, Hälsouniversitetet.
    Wiréhn, Ann-Britt
    Linköpings universitet, Institutionen för medicin och hälsa, Hälsa och samhälle. Linköpings universitet, Hälsouniversitetet.
    Bourghardt Peebo, Beatrice
    Linköpings universitet, Institutionen för klinisk och experimentell medicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Sinnescentrum, Ögonkliniken US/LiM.
    Rosenqvist, Ulf
    Östergötlands Läns Landsting, Närsjukvården i västra Östergötland, Medicinska specialistkliniken .
    Levin, Lars-Åke
    Linköpings universitet, Institutionen för medicin och hälsa, Utvärdering och hälsoekonomi. Linköpings universitet, Hälsouniversitetet.
    QALY weights for diabetic retinopathy: a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO.2012Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, nr 3, s. 475-484Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objective: To estimate quality-adjusted life-year weights for patients with diabetic retinopathy by using various methods and to investigate the empirical validity of the different measures.

    Methods: The study population comprised 152 patients with diabetes in Östergötland County, Sweden. Participants were interviewed by telephone by using the time trade-off (TTO) method and a visual analogue scale (EQ-VAS) (direct valuations) as well as the EuroQol five-dimensional questionnaire (EQ-5D) and the health utilities index mark 3 (HUI-3) (indirect valuations). The quality-adjusted life-year weights were adjusted for potential confounders by using analysis of covariance. The empirical validity of the measures was examined by testing their ability to detect hypothetical differences between severity levels of diabetic retinopathy and by investigating the correlation between the measures and the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25).

    Results: All measures detected significant differences in scores between patient groups classified according to visual impairment in the better eye (analysis of covariance, P < 0.05), but only HUI-3 and EQ-VAS detected significant differences between patient groups classified according to visual impairment or pathological progression in the worse eye. HUI-3 recorded a difference of 0.43 in values between normal vision and blindness in the better eye, which was more than twice the differences captured by the other measures (0.15–0.20). In addition, HUI-3 showed the highest correlation with NEI VFQ-25 (r = 0.54; P < 0.001).

    Conclusions: In cost-utility analyses, the choice of quality-adjusted life-year measure may affect whether an intervention is considered cost-effective. Furthermore, if decisions are to be based on values from the general public, HUI-3 can be recommended for cost-utility analyses of interventions directed at diabetic retinopathy.

  • 35.
    Hidefjäll, Patrik
    KTH, Skolan för teknik och hälsa (STH).
    Ensuring The Value Of A Medical Device Innovation Prior To Market Launch2012Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, nr 7, s. A490-A490Artikkel i tidsskrift (Annet vitenskapelig)
  • 36.
    Hidefjäll, Patrik
    KTH, Skolan för teknik och hälsa (STH).
    Stakeholder Involvement In Health Technology Assessment (HTA) Of Novel Medical Devices2012Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 15, nr 7, s. A324-A324Artikkel i tidsskrift (Annet vitenskapelig)
  • 37.
    Holm-Larsen, Tove
    et al.
    Pharma Evidence, Denmark; University of Copenhagen, Denmark.
    Andersson, Fredrik
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för hälso- och sjukvårdsanalys. Linköpings universitet, Medicinska fakulteten.
    van der Meulen, Egbert
    Ferring Int PharmaScience Centre, Denmark.
    Yankov, Vladimir
    Ferring Pharmaceut Inc, NJ USA.
    Rosen, Raymond C.
    New England Research Institute, MA USA.
    Peter Norgaard, Jens
    Ferring Int PharmaScience Centre, Denmark.
    The Nocturia Impact Diary: A Self-Reported Impact Measure to Complement the Voiding Diary2014Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, nr 6, s. 696-706Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Nocturia is a chronic, fluctuating disease that disrupts sleep and has a wide-ranging impact on quality of life. Valid tools to measure the patient-reported impact of nocturia are essential for evaluating the value of treatment, but the available tools are suboptimal. Objectives: This study reports the development and validation of the Nocturia Impact Diary an augmented form of the Nocturia Quality of Life questionnaire designed to be completed in conjunction with the widely used 3-day voiding diary. Methods: The process comprised three steps: Step 1: Development of a concept pool using the Nocturia Quality of Life questionnaire and data from relevant studies; Step 2: Content validity study; Step 3: Psychometric testing of construct validity, reliability, and sensitivity of the diary in a randomized, placebo controlled study in patients with nocturia. Results: Step 1: Fourteen items and 4 domains were included in the first draft of the diary. Step 2: Twenty-three patients with nocturia participated in the cognitive debriefing study. Items were adjusted accordingly, and the content validity was high. Step 3: Fifty-six patients were randomized to desmopressin orally disintegrating tablet or placebo. The diary demonstrated high construct validity, with good sensitivity and a good fit to Rasch model, as well as high internal consistency, discriminatory ability, and acceptable sensitivity to change. Results indicated that the diary was unidimensional. Conclusions: The Nocturia Impact Diary is a convenient, validated patient-reported outcome measure it should be used in conjunction with a voiding diary to capture the real-life consequences of nocturia and its treatment.

    Fulltekst (pdf)
    fulltext
  • 38. Hoogendoorn, Martine
    et al.
    Feenstra, Talitha L
    Asukai, Yumi
    Briggs, Andrew H
    Borg, Sixten
    Dal Negro, Roberto W
    Hansen, Ryan N
    Jansson, Sven-Arne
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Yrkes- och miljömedicin.
    Leidl, Reiner
    Risebrough, Nancy
    Samyshkin, Yevgeniy
    Wacker, Margarethe E
    Rutten-van Mölken, Maureen P M H
    Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?2016Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 19, nr 6, s. 800-810Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    OBJECTIVES: To assess how suitable current chronic obstructive pulmonary disease (COPD) cost-effectiveness models are to evaluate personalized treatment options for COPD by exploring the type of heterogeneity included in current models and by validating outcomes for subgroups of patients.

    METHODS: A consortium of COPD modeling groups completed three tasks. First, they reported all patient characteristics included in the model and provided the level of detail in which the input parameters were specified. Second, groups simulated disease progression, mortality, quality-adjusted life-years (QALYs), and costs for hypothetical subgroups of patients that differed in terms of sex, age, smoking status, and lung function (forced expiratory volume in 1 second [FEV1] % predicted). Finally, model outcomes for exacerbations and mortality for subgroups of patients were validated against published subgroup results of two large COPD trials.

    RESULTS: Nine COPD modeling groups participated. Most models included sex (seven), age (nine), smoking status (six), and FEV1% predicted (nine), mainly to specify disease progression and mortality. Trial results showed higher exacerbation rates for women (found in one model), higher mortality rates for men (two models), lower mortality for younger patients (four models), and higher exacerbation and mortality rates in patients with severe COPD (four models).

    CONCLUSIONS: Most currently available COPD cost-effectiveness models are able to evaluate the cost-effectiveness of personalized treatment on the basis of sex, age, smoking, and FEV1% predicted. Treatment in COPD is, however, more likely to be personalized on the basis of clinical parameters. Two models include several clinical patient characteristics and are therefore most suitable to evaluate personalized treatment, although some important clinical parameters are still missing.

  • 39.
    Jaldell, Henrik
    Karlstads universitet, Fakulteten för humaniora och samhällsvetenskap (from 2013), Handelshögskolan (from 2013).
    HOW IMPORTANT IS THE TIME FACTOR?: SAVING LIVES USING FIRE AND RESCUE SERVICES2015Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 7, s. A535-A535Artikkel i tidsskrift (Fagfellevurdert)
  • 40.
    Jaldell, Henrik
    et al.
    Karlstads universitet, Fakulteten för humaniora och samhällsvetenskap (from 2013), Handelshögskolan.
    Lebnak, Prachaksvich
    Emergency Medical Institute Thailand, Bangkok.
    Amornpetchsathaporn, Anurak
    Emergency Medical Institute Thailand, Bangkok.
    Time Is Money, But How Much? The Monetary Value of Response Time for Thai Ambulance Emergency Services2014Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 17, nr 5, s. 555-560Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    ObjectiveTo calculate the monetary value of the time factor per minute and per year for emergency services.MethodsThe monetary values for ambulance emergency services were calculated for two different time factors, response time, which is the time from when a call is received by the emergency medical service call-taking center until the response team arrives at the emergency scene, and operational time, which includes the time to the hospital. The study was performed in two steps. First, marginal effects of reduced fatalities and injuries for a 1-minute change in the time factors were calculated. Second, the marginal effects and the monetary values were put together to find a value per minute.ResultsThe values were found to be 5.5 million Thai bath/min for fatality and 326,000 baht/min for severe injury. The total monetary value for a 1-minute improvement for each dispatch, summarized over 1 year, was 1.6 billion Thai baht using response time.ConclusionsThe calculated values could be used in a cost-benefit analysis of an investment reducing the response time. The results from similar studies could for example be compared to the cost of moving an ambulance station or investing in a new alarm system.

  • 41.
    Janssens, R.
    et al.
    Univ Leuven, Leuven, Belgium..
    Huys, I
    Katholieke Univ Leuven, Leuven, Belgium..
    van Overbeeke, E.
    Univ Leuven, Leuven, Belgium..
    Whichello, C.
    Erasmus Univ, Rotterdam, Netherlands..
    de Bekker-Grob, E.
    Erasmus Univ, Rotterdam, Netherlands..
    Kuebler, J.
    QSciCon, Marburg, Germany..
    Harding, S.
    Takeda Dev Ctr Europe Ltd, London, England..
    Juhaeri, J.
    Sanofi, Bridgewater, NJ USA..
    Levitan, B.
    Janssen R&D, Titusville, NJ USA..
    Cleemput, I
    Belgian Hlth Care Knowledge Inst KCE, Brussels, Belgium..
    Russo, S.
    European Inst Oncol, Milan, Italy..
    Schölin Bywall, Karin
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Centrum för forsknings- och bioetik.
    Veldwijk, Jorien
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Centrum för forsknings- och bioetik.
    Stakeholder Perspectives On The Integration Of Patient Preferences In The Medical Product Life Cycle: A Multimethod Approach2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A689-A689Artikkel i tidsskrift (Annet vitenskapelig)
  • 42. Jansson, S. A.
    et al.
    Stenling, A.
    AstraZeneca Nordic MC.
    Backman, H.
    Ronmark, E.
    Lindberg, A.
    Lundback, B.
    Health care costs of individuals with and without COPD in Sweden2010Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 13, nr 7, s. A321-A321Artikkel i tidsskrift (Annet vitenskapelig)
  • 43.
    Jansson, Sven-Arne
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Yrkes- och miljömedicin.
    Backman, Helena
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Yrkes- och miljömedicin.
    Andersson, M.
    Telg, G.
    Lundbäck, B.
    Rönmark, Eva
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Yrkes- och miljömedicin.
    Health care consumption and HRQOL in severe asthma in Sweden2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A513-A513Artikkel i tidsskrift (Annet vitenskapelig)
    Abstract [en]

    Objectives: Severe asthma is a disabling and costly disease, often poorly controlled despite high-dosage controller medications. The objectives of this analysis were to estimate health care consumption and to investigate health-related quality of life (HRQOL) in a severe asthma cohort, derived from a large-scale population survey in northern Sweden. Methods: Severe asthma was defined by US SARP criteria; high-dosage inhaled corticosteroids (ICS) by GINA 2014 criteria. In total, 32 patients with severe asthma were invited to a clinical examination and structured interview. Retrospective data of all asthma-related direct and indirect resource consumption during the last year were collected following a defined protocol. HRQOL was assessed by four patient-reported outcome measures: two general measures (SF-36; EQ-5D) and two disease-specific measures (SGRQ; ACT). The cohort was divided into two groups —patients with (OCS) or without maintenance oral corticosteroid (non-OCS) treatment. Results: Health care resource utilization was greater in the OCS-group compared with the non-OCS group. Mean annual number of visits to specialist care was 2.0 in the OCS group vs. 0.5 visits in the non-OCS group. Four patients in the OCS group had early retirement vs. none in the non-OCS group. HRQOL was worse in the OCS group, both when measured with general and disease-specific instruments. The Mental and Physical Component Summary scores of the SF-36 in the OCS vs. non-OCS group were 50.1 vs. 40.7 and 55.8 vs. 44.4, respectively. Similarly, the total SGRQ scores indicated worse HRQOL for the OCS-group compared with the non-OCS group (37.0 vs. 27.0). Conclusions: In this severe asthma population, patients treated with maintenance OCS consumed more health care resources, were more frequently early retired, and had worse HRQOL compared with those not receiving maintenance OCS. The results indicate a need for improved treatment for patients with severe asthma on maintenance OCS. Sponsor: AstraZeneca.

  • 44.
    Jendle, Johan
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Birkenfeld, A. L.
    Technical University Dresden, Dresden, Germany.
    Silver, R.
    Southern New Hampshire Diabetes and Endocrinology, Nashua NH, USA.
    Uusinarkaus, K.
    CSHP / DaVita Clinical Research, Colorado Springs CO, USA.
    Højbjerre, L.
    Novo Nordisk A/S, Søborg, Denmark.
    Thomsen, H. F.
    Novo Nordisk A/S, Søborg, Denmark.
    Davies, M.
    Diabetes Research Centre, University of Leicester, Leicester, UK.
    Effect of Gastrointestinal Adverse Events on Treatment Satisfaction in Semaglutide Treatment of Type 2 Diabetes2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A484-A484Artikkel i tidsskrift (Annet vitenskapelig)
  • 45.
    Jendle, Johan
    et al.
    Örebro universitet, Institutionen för hälsovetenskap och medicin.
    Ridderstrale, M.
    Steno Diabetes, Gentofte, Denmark.
    Jensen, H. H.
    Incentive, Holte, Denmark.
    Bøgelund, M.
    Incentive, Holte, Denmark..
    Jensen, M. M.
    Novo Nordisk, Copenhagen, Denmark.
    Ericsson, A.
    Novo Nordisk Scandinavia AB, Malmö, Sweden.
    Evans, M.
    University Hospital Llandough, Cardiff, UK.
    Investigating the short-term impact of poor glycemic control on the daily lives of people with type 2 diabetes2015Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 3, s. A65-A65Artikkel i tidsskrift (Annet vitenskapelig)
  • 46.
    Jendle, Johan
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Thunander, M.
    Lund University, Lund, Sweden.
    Ekman, B.
    Linköping University, Linköping, Sweden.
    Sjöberg, S.
    Karolinska Institutet, Stockholm, Sweden .
    Ericsson, Å.
    Novo Nordisk Scandinavia AB, Malmö, Sweden.
    da Rocha Fernandes, J.
    Novo Nordisk A/S, Søborg, Denmark.
    Mårdby, A.C.
    Novo Nordisk Scandinavia AB, Malmö, Sweden.
    Malkin, S.J.P.
    Ossian Health Economics and Communications, Basel, Switzerland.
    Hunt, B.
    Ossian Health Economics and Communications, Basel, Switzerland.
    Switching to insulin degludec is a cost-saving therapy for patients with type 1 and type 2 diabetes in the Swedish setting based on real world data2019Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 22, nr Suppl. 3, s. 575-576Artikkel i tidsskrift (Annet vitenskapelig)
    Abstract [en]

    Objectives: The Europe-based, prospective, observational ReFLeCT study recently showed that switching to the ultralong-acting basal insulin analogue degludec (IDeg) was associated with improved glycemic control and reductions in hypoglycemic events versus previous basal insulin therapies in patients with type 1 (T1D) or type 2 diabetes (T2D). The present analysis aimed to assess the impact of thesefindings on long-term cost-effectiveness outcomes in the Swedish setting.

    Methods: Cost-effectiveness was evaluated separately in patients with T1D and T2D over a 50-year time horizon using the IQVIA CORE Diabetes Model (version 9.0). Patients were assumed to receive IDeg or continue previous insulin therapy (with or without bolus insulin) for 5 years, before all patients intensified to insulin degludec plus bolus insulin for the remainder of their lifetimes. Baseline cohort characteristics were sourced from ReFLeCT where possible. Treatment effects on initiation of IDeg were based on data from ReFLeCT. Costs were estimated from a Swedish societal perspective and expressed in 2018 Swedish krona (SEK).

    Results: IDeg was associated with improvements in quality-adjusted life expectancy of 0.14 and 0.07 quality-adjusted life years versus continuation of previous insulin therapy in patients with T1D and T2D, respectively, resulting from improved glycemic control and fewer hypoglycemic events. Combined direct and indirect costs were estimated to be SEK 137,020 and SEK 2,009 lower for insulin degludec versus previous insulin therapy in patients with T1D and T2D, respectively, with higher treatment costs offset by cos tsavings from avoidance of diabetes-related complications. IDeg was therefore considered dominant versus continuation of previous insulin therapies for the treatment of both T1D and T2D.

    Conclusions: Based on real-world evidence, IDeg represents an effective and cost-saving treatment option versus other basal insulin therapies for patients with T1D and T2D in Sweden.

  • 47. Jensen, A. , V
    et al.
    Fraenkel, C. J.
    Skåne Univ Hosp, Lund, Sweden.
    Akesson, P.
    Skåne Univ Hosp, Lund, Sweden.
    Norén, Torbjörn
    Region Örebro län.
    Rundlof Nygren, P.
    Uppsala Univ Hosp, Uppsala, Sweden.
    Lennebratt, D.
    Uppsala Univ Hosp, Uppsala, Sweden.
    Hagberg, L.
    Sahigrenska Univ Hosp, Gothenburg, Sweden.
    The Cost Of Treating Recurrent Clostridium Difficile Infection In Patients Attending Infectious Disease Clinics At Four Hospitals In Sweden2015Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, nr 7, s. A583-A583Artikkel i tidsskrift (Fagfellevurdert)
  • 48. Johansson, S
    et al.
    Farahmand, B
    Joelson, S
    Estborn, L
    Wallander, Mari-Ann
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Allmänmedicin och preventivmedicin.
    Risk of upper gastrointestinal adverse events and the effect of acid-suppressive theraphy in patients receiving acetylsalicylic acid for cardiovascular risk management2009Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 12, nr 3, s. A58-Artikkel i tidsskrift (Fagfellevurdert)
  • 49.
    Jonsson, E.
    et al.
    Quantify Res, Stockholm, Sweden..
    Hanson-Hedblom, A.
    Quantify Res, Stockholm, Sweden..
    Kirketeig, Terje
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper, Anestesiologi och intensivvård.
    Fritzell, P.
    Capio St Goran Hosp, Stockholm, Sweden..
    Hagg, O.
    Spine Ctr Goteborg, Gothenburg, Sweden..
    Borgstrom, F.
    Quantify Res, Stockholm, Sweden..
    Societal Cost Patterns By Spine Surgical Outcome Groups And Patients Treated With Spinal Cord Stimulation Following Spine Surgery2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A553-A553Artikkel i tidsskrift (Annet vitenskapelig)
  • 50.
    Jonsson, E.
    et al.
    Quantify Res, Stockholm, Sweden..
    Strom, O.
    Quantify Res, Stockholm, Sweden.;Karolinska Inst, LIME MMC, Stockholm, Sweden..
    Spangeus, A.
    Linkoping Univ Hosp, Linkoping, Sweden..
    Akesson, K.
    Lund Univ, Skane Univ Hosp, Malmo, Sweden..
    Ljunggren, Östen
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Endokrinologi och mineralmetabolism.
    Borgstrom, R.
    Quantify Res, Stockholm, Sweden.;Karolinska Inst, LIME MMC, Stockholm, Sweden..
    Banefelt, J.
    Quantify Res, Stockholm, Sweden..
    Toth, E.
    UCB Pharma, Brussels, Belgium..
    Libanati, C.
    UCB Pharma, Brussels, Belgium..
    Charokopou, M.
    UCB Pharma, Brussels, Belgium..
    Risk Of Major Osteoporotic Fracture (Hip, Vertebral, Radius, Humerus [Mof]) After First, Second And Third Fragility Fracture In A Swedish General Population Cohort2017Inngår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 20, nr 9, s. A528-A528Artikkel i tidsskrift (Annet vitenskapelig)
123 1 - 50 of 110
RefereraExporteraLink til resultatlisten
Permanent link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf